Influence of estradiol and triiodothyronine on breast cancer cell lines proliferation and expression of estrogen and thyroid hormone receptors.

OBJECTIVE To better understand the estrogen (E2) agonist action of triiodothyronine (T3) the effects of these hormones on ER negative MDA-MB-231 breast cancer cells were compared with those on S30, a clone of MDA-MB-231 stably transfected with ERalpha cDNA, in terms of proliferation and modulation of hormone receptors. RESULTS Growth experiments showed that MDA-MB-231 was not modulated by any hormone or tamoxifen (TAM). Treatment with E2, 10(-8)M or 10(-9)M had little effect on S30 proliferation. T3 at 10(-8)M significantly inhibited proliferation. This effect was not reverted by TAM. Treatments with 10(-8)M concentration of E2 or T3 reduced ERalpha gene expression in S30, an effect partially blocked by association with TAM, with no effect on TR expression. These results suggest that, in S30, 10(-8)M T3 has a similar action to E2 relative to ERalpha gene modulation. CONCLUSIONS Such results emphasize the need of determining T3 levels, before the introduction of antiestrogenic forms of treatment in breast cancer patients.

[1]  E. Levin.  Plasma membrane estrogen receptors , 2009, Trends in Endocrinology & Metabolism.

[2]  E. Salazar,et al.  Effects of thyroid hormones on human breast cancer cell proliferation , 2008, The Journal of Steroid Biochemistry and Molecular Biology.

[3]  N. Davidson,et al.  Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes. , 2006, Cancer research.

[4]  B. Fraile,et al.  Influence of thyroid hormone receptors on breast cancer cell proliferation. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  M. Brentani,et al.  Profile of thyroid hormones in breast cancer patients. , 2005, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[6]  I Kimber,et al.  Anti-proliferative effect of estrogen in breast cancer cells that re-express ERalpha is mediated by aberrant regulation of cell cycle genes. , 2005, Journal of molecular endocrinology.

[7]  G. Hortobagyi,et al.  Thyroid hormone and breast carcinoma , 2005, Cancer.

[8]  F. B. Davis,et al.  Thyroid hormone causes mitogen-activated protein kinase-dependent phosphorylation of the nuclear estrogen receptor. , 2004, Endocrinology.

[9]  R. Hovey,et al.  Establishing a Framework for the Functional Mammary Gland: From Endocrinology to Morphology , 2004, Journal of Mammary Gland Biology and Neoplasia.

[10]  D. Bentrem,et al.  Stable transfection of an estrogen receptor beta cDNA isoform into MDA-MB-231 breast cancer cells , 2003, The Journal of Steroid Biochemistry and Molecular Biology.

[11]  S. Demirbaş,et al.  Breast cancer in association with thyroid disorders , 2003, Breast Cancer Research.

[12]  A. Muñoz,et al.  Thyroid hormone receptors/THR genes in human cancer. , 2003, Cancer letters.

[13]  V. Moudgil,et al.  Estrogen-like effects of thyroid hormone on the regulation of tumor suppressor proteins, p53 and retinoblastoma, in breast cancer cells , 2002, Oncogene.

[14]  C. Markopoulos,et al.  Autoimmune thyroid disease in women with breast carcinoma. , 2001, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[15]  A. Lucas,et al.  ERβ Inhibits Proliferation and Invasion of Breast Cancer Cells. , 2001, Endocrinology.

[16]  A. Lucas,et al.  ER beta inhibits proliferation and invasion of breast cancer cells. , 2001, Endocrinology.

[17]  J. Gustafsson,et al.  Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. , 1997, Science.

[18]  M. Brentani,et al.  Triiodothyronine mimics the effects of estrogen in breast cancer cell lines , 1996, The Journal of Steroid Biochemistry and Molecular Biology.

[19]  P. Bontempo,et al.  Tyrosine kinase/p21ras/MAP‐kinase pathway activation by estradiol‐receptor complex in MCF‐7 cells. , 1996, The EMBO journal.

[20]  V. Jordan,et al.  Paradoxical regulation of estrogen-dependent growth factor gene expression in estrogen receptor (ER)-negative human breast cancer cells stably expressing ER. , 1994, Cancer letters.

[21]  H. Rochefort,et al.  Activation of estrogen receptor transfected into a receptor-negative breast cancer cell line decreases the metastatic and invasive potential of the cells. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[22]  V. Jordan,et al.  Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor. , 1992, Journal of the National Cancer Institute.

[23]  M. Joly-Pharaboz,et al.  Antiestrogens prevent the stimulatory effects of L-triiodothyronine on cell proliferation. , 1992, Endocrinology.

[24]  H. Rochefort,et al.  Inhibition of breast cancer growth by suramin. , 1992, Journal of the National Cancer Institute.

[25]  I. Touitou,et al.  Hormonal regulation of cathepsin D following transfection of the estrogen or progesterone receptor into three sex steroid hormone resistant cancer cell lines , 1991, The Journal of Steroid Biochemistry and Molecular Biology.

[26]  H. Vorherr.  Thyroid function in benign and malignant breast disease. , 1987, European journal of cancer & clinical oncology.

[27]  B. Vonderhaar,et al.  Thyroid hormone regulation of epidermal growth factor receptor levels in mouse mammary glands. , 1986, Endocrinology.

[28]  Y. J. Topper,et al.  Multiple hormone interactions in the developmental biology of the mammary gland. , 1980, Physiological reviews.

[29]  F. Greenspan,et al.  Thyroid supplementation for hypothyroidism. An latrogenic cause of breast cancer? , 1977, JAMA.

[30]  J. Wolfe,et al.  Breast cancer. Relationship to thyroid supplements for hypothyroidism. , 1976, JAMA.